The Full Story
iCE Neuro launches with $700,000 in startup funds.
FDA grants Emergency Use authorization for use of the iCEWav Neuromonitoring Platform with subcutaneous electrodes for a critically ill COVID patient.
FDA grants 510(k) clearance for the iCEWav Neuromonitoring software platform.
iCEWav becomes an integral component of care for critically ill COVID patients.
iCE Neuro completes landmark trial of iCE-SG electrodes in patients with cardiac arrest.
iCE Neuro raises $2.95M in seed funding to accelerate clinical adoption and catalyze big-data analysis.
FDA grants 510(k) clearance for iCE-SG Subcutaneous Electrode arrays.